LXRX

Today, 7:41 AMLexicon Pharmaceuticals posts Q3 net loss of $14M on $11.3M revenue and reports STENO1 safety data for Q1 2027 ZYNQUISTA resubmission

Peers: ARDX MLYS PHAT MNKD TVTX KARD TECX VNDA RZLT DWTX

| Held by: VTI IWM VXF XPH IWO VTWO SCHA VHT IWC VFMO

Scroll to Statements

Index	RUT
Market Cap	707.47M
Enterprise Value	576.10M
Income	-61.12M
Sales	41.47M
Book/sh	0.39
Cash/sh	0.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	81
IPO	Apr 07, 2000

P/E	-
Forward P/E	-
PEG	-
P/S	17.06
P/B	4.05
P/C	3.71
P/FCF	-
EV/EBITDA	-
EV/Sales	13.89
Quick Ratio	13.29
Current Ratio	13.37
Debt/Eq	0.34
LT Debt/Eq	0.33
Option/Short	Yes / Yes

EPS (ttm)	-0.15
EPS next Y	-0.21
EPS next Q	-0.04
EPS this Y	-19.31%
EPS next Y	-26.37%
EPS next 5Y	6.60%
EPS past 3/5Y	39.13% 23.47%
Sales past 3/5Y	610.25% 15.72%
EPS Y/Y TTM	54.11%
Sales Y/Y TTM	-29.03%
EPS Q/Q	-915.73%
Sales Q/Q	-97.60%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	46.90% 171.43%

Insider Own	50.79%
Insider Trans	0.00%
Inst Own	33.95%
Inst Trans	5.24%
ROA	-25.70%
ROE	-40.21%
ROIC	-26.33%
Gross Margin	97.98%
Oper. Margin	-131.43%
Profit Margin	-147.38%
SMA20	3.94%
SMA50	-12.75%
SMA200	-15.73%
Trades

Shs Outstand	444.94M
Shs Float	218.98M
Short Float	12.19%
Short Ratio	10.06
Short Interest	26.70M
52W High	2.68 -40.67%
52W Low	1.10 44.55%
Volatility	5.87% 5.53%
ATR (14)	0.09
RSI (14)	48.02
Beta	1.09
Rel Volume	1.56
Avg Volume	2.65M
Volume	2,471,065

Perf Week	7.43%
Perf Month	-9.66%
Perf Quarter	-35.63%
Perf Half Y	-5.36%
Perf YTD	38.26%
Perf Year	15.22%
Perf 3Y	7.43%
Perf 5Y	-67.15%
Perf 10Y	-88.94%
Recom	1.67
Target Price	4.46
Prev Close	1.48
Price	1.59
Change %	7.43%

Consensus

Buy

Avg. Price Target

$4.46

Implied Upside

+180.5%

Analysts11incl. previous ratings

Rating Distribution5 Buy · 6 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 28, 2026	Initiated	CCantor Fitzgerald	Overweight	$8	+403.1%
Mar 05, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$2 → $1	-37.1%
Jun 17, 2024	Initiated	HH.C. Wainwright	Buy	$10	+528.9%
Apr 30, 2024	Initiated	LLeerink Partners	Outperform	$5	+214.5%
Mar 07, 2023	Initiated	JJefferies	Hold	$3	+88.7%
Aug 12, 2022	Initiated	PPiper Sandler	Overweight	$10	+528.9%
Jan 29, 2021	Upgrade	JJP Morgan	Underweight → Neutral	$7	+340.3%
Jan 29, 2021	Downgrade	WWedbush	Outperform → Neutral	$2 → $8	+403.1%
Dec 08, 2020	Upgrade	CCitigroup	Neutral → Buy
Nov 18, 2020	Upgrade	GGabelli & Co	Hold → Buy
Dec 11, 2019	Downgrade	GGabelli & Co	Buy → Hold
Nov 08, 2019	Downgrade	CCitigroup	Buy → Neutral	$3 → $4	+151.6%
Sep 11, 2019	Upgrade	GGabelli & Co	Hold → Buy	$3	+88.7%
Jul 29, 2019	Downgrade	SStifel	Buy → Hold	$10 → $4	+151.6%
Mar 25, 2019	Upgrade	GGabelli & Co	Sell → Hold
Jul 31, 2018	Reiterated	SStifel	Buy	$24 → $23	+1,346.5%
Feb 23, 2018	Downgrade	NNeedham	Buy → Hold
Feb 14, 2018	Downgrade	JJP Morgan	Neutral → Underweight	$10	+528.9%
Mar 01, 2017	Reiterated	WWedbush	Outperform	$33 → $38	+2,289.9%
Mar 01, 2017	Reiterated	HH.C. Wainwright	Buy	$26 → $27	+1,598.1%

Today 10:03AM	Lexicon's EPS Beat Owes Much To Dilution As SONATA-HCM And STENO1 Progress Collide With A Third ZYNQUISTA Delay (Earnings Whispers) +7.43%
07:22AM	Lexicon: Q3 Earnings Snapshot (Associated Press)
07:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire)
Oct-29-26 11:57AM	Lexicon Heads Into Q3 Needing Proof The Zynquista Refiling Finally Landed On Time (Earnings Whispers)
08:30AM	Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
08:30AM	Loading…
Oct-23-26 08:30AM	Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy (GlobeNewswire)
Oct-21-26 08:30AM	Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease (GlobeNewswire)
Sep-28-26 12:10PM	Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM (Investing.com) +5.85%
Sep-01-26 04:05PM	Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-31-26 08:30AM	Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure (GlobeNewswire)
Aug-24-26 01:27PM	LXRX Stock Edges Higher On $10M Payout From Novo Nordisk Retail Traders Highlight More Cash Milestones On The Horizon (Stocktwits)
08:30AM	Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 (GlobeNewswire)
Aug-06-26 07:18PM	Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ... (GuruFocus.com)
07:56AM	Lexicon: Q2 Earnings Snapshot (Associated Press)
07:30AM	Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire)
08:30AM	Loading…
Jul-30-26 08:30AM	Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-27-26 08:30AM	Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) (GlobeNewswire)
Jun-03-26 08:00AM	Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions (GlobeNewswire)
May-28-26 08:30AM	Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 08:30AM	Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-07-26 07:46AM	Lexicon: Q1 Earnings Snapshot (Associated Press)
07:30AM	Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire)
May-04-26 04:05PM	Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital (GlobeNewswire)
Apr-30-26 08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-17-26 08:00AM	Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire)
Mar-24-26 08:00AM	Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-23-26 07:30AM	Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 (GlobeNewswire) +5.13%
Mar-11-26 08:00AM	Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes (GlobeNewswire)
Mar-10-26 11:26AM	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study (Zacks)
Mar-05-26 10:10PM	Lexicon Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
07:21AM	Loading…
07:21AM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
06:59AM	Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates (GlobeNewswire)
Mar-04-26 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-03-26 04:01PM	Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-26 08:30AM	Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 (GlobeNewswire)
Feb-06-26 05:17PM	Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-30-26 02:58PM	Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones (Insider Monkey) -19.44%
02:50AM	Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-29-26 04:31PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:05AM	Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Jan-23-26 08:30AM	Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary (GlobeNewswire)
Jan-21-26 08:30AM	Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +19.08%
Jan-12-26 07:30AM	Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 08:30AM	Lexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain" (GlobeNewswire)
Jan-07-26 08:30AM	Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 08:30AM	Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 (GlobeNewswire)
Dec-05-25 08:30AM	Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum (GlobeNewswire)
Nov-25-25 08:30AM	Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences (GlobeNewswire)
Nov-24-25 09:47AM	Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development (Insider Monkey) +5.97%
Nov-11-25 08:30AM	Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference (GlobeNewswire) +9.86%
Nov-08-25 02:30PM	Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 (GlobeNewswire)
Nov-06-25 08:50AM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:47AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates (GlobeNewswire)
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:30AM	Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans (GlobeNewswire)
Oct-30-25 08:30AM	Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit (GlobeNewswire)
Oct-08-25 07:59AM	Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain (GlobeNewswire) -5.92%
Sep-22-25 04:00PM	Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-17-25 07:00AM	Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings (GlobeNewswire)
Sep-11-25 08:30AM	Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings (GlobeNewswire)
Sep-08-25 08:30AM	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-04-25 08:30AM	Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 (GlobeNewswire)
Sep-03-25 08:30AM	Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 (GlobeNewswire)
Sep-02-25 08:30AM	Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress (GlobeNewswire)
Aug-27-25 08:30AM	Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 12:00PM	Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-25 08:45AM	Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates (Zacks) +9.52%
07:47AM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-25 06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks) -6.25%
Jul-31-25 08:00AM	Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-23-25 08:00AM	Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) (Insider Monkey)
Jul-18-25 08:00AM	Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) (GlobeNewswire) -8.89%
Jun-23-25 08:00AM	Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-18-25 08:30AM	Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks) -5.91%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +6.93%
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks) +8.46%
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -5.03%
08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks) -5.66%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
08:00AM	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swain Judith L	Director	Jun 03 '26	Option Exercise	0.00	89,312	0	174,486	Jun 04 04:14 PM
Sullivan Diane E.	Director	Jun 03 '26	Option Exercise	0.00	89,312	0	126,122	Jun 04 04:13 PM
SOBECKI CHRISTOPHER J	Director	Jun 03 '26	Option Exercise	0.00	89,312	0	293,177	Jun 04 04:13 PM
Cheung Ivan	Director	Jun 03 '26	Option Exercise	0.00	89,312	0	89,312	Jun 04 04:12 PM
BARKER SAM L	Director	Jun 03 '26	Option Exercise	0.00	89,312	0	213,771	Jun 04 04:11 PM
Amouyal Philippe	Director	Jun 03 '26	Option Exercise	0.00	89,312	0	374,486	Jun 04 04:10 PM
DEBBANE RAYMOND	Director	Jun 03 '26	Option Exercise	0.00	89,312	0	1,995,498	Jun 04 04:09 PM
Artal Participations S.a r.l.	Director	Apr 30 '26	Option Exercise	0.00	20,421,735	0	175,156,062	May 08 09:45 PM
DEBBANE RAYMOND	Director	Feb 25 '26	Buy	1.49	2,000	2,980	1,906,186	Feb 27 08:33 AM
DEBBANE RAYMOND	Director	Feb 23 '26	Buy	1.47	100,000	147,000	1,904,186	Feb 25 07:00 AM
DEBBANE RAYMOND	Director	Feb 20 '26	Buy	1.48	100,000	147,790	1,804,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 19 '26	Buy	1.44	50,000	71,965	1,704,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 18 '26	Buy	1.32	133,688	176,468	1,654,186	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 17 '26	Buy	1.31	76,857	100,544	1,520,498	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 13 '26	Buy	1.31	57,952	75,877	1,443,641	Feb 18 04:30 PM
Invus Global Management, LLC	Director	Feb 02 '26	Buy	1.30	1,538,462	2,000,001	1,538,462	Feb 04 04:25 PM

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

CEO & DirectorDr. Michael S. Exton Ph.D.

Senior VP & CFOMr. Scott M. Coiante

Senior VPMr. Brian T. Crum

Senior Vice President of Human ResourcesMs. Wendy E. McDermott

Ph.D.Dr. Craig B. Granowitz M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Lexicon Pharmaceuticals Inc

Upgrade your Finviz experience